2020
HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
Zhao J, Krishnamurti U, Zhang C, Meisel J, Wei Z, Suo A, Aneja R, Li Z, Li X. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer. Pathology - Research And Practice 2020, 216: 153155. PMID: 32871536, DOI: 10.1016/j.prp.2020.153155.Peer-Reviewed Original ResearchConceptsHigh HER2/CEP17 ratioHER2/CEP17 ratioTumor responseBreast cancer casesNeoadjuvant HER2CEP17 ratioNeoadjuvant chemotherapyIHC 3Breast cancerCancer casesRCB II/IIIHER2-positive breast cancerHER2 IHC 3Complete pathologic responseResidual cancer burdenSmaller tumor sizePositive breast cancerLow nuclear gradeHER2 copy numberHigh Ki67Pathologic responseCancer burdenExcisional specimensPositive cancersTumor sizeDo High Rates of Atypical Glandular Cells Correlate With Higher Incidence of Disease in a Large Safety Net Hospital.
Kuhn T, Finneran C, Kohut A, Wang E, Birdsong G, Krishnamurti U, Mosunjac M, Tadros T, Oprea G, Avadhani V, Boguslawski S, Karlow S, Schnatz P, Khanna N, Flowers L. Do High Rates of Atypical Glandular Cells Correlate With Higher Incidence of Disease in a Large Safety Net Hospital. Journal Of Lower Genital Tract Disease 2020, 24: 353-357. PMID: 32569024, DOI: 10.1097/lgt.0000000000000556.Peer-Reviewed Original ResearchConceptsAGC Pap testsAbnormal uterine bleedingPap testUterine bleedingHPV positivityHuman papillomavirusLarge safety net hospitalBody mass indexHigh-risk lesionsLow-risk lesionsSafety-net hospitalLow socioeconomic statusBaseline characteristicsEndometrial biopsyMass indexSingle institutionMedical recordsNet hospitalHigh incidencePatientsLesionsSignificant associationHR lesionsBleedingLogistic regressionDetection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer
Maliniak M, Cheriyan A, Sherman M, Liu Y, Gogineni K, Liu J, He J, Krishnamurti U, Miller-Kleinhenz J, Ashiqueali R, He J, Yacoub R, McCullough L. Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer. Breast Cancer Research 2020, 22: 65. PMID: 32552729, PMCID: PMC7298873, DOI: 10.1186/s13058-020-01308-4.Peer-Reviewed Original ResearchConceptsBreast adipose tissueHazard ratioBreast cancerAdipose tissueMultivariable Cox proportional hazards modelsWhite womenCox proportional hazards modelProgression-free survivalMedical record reviewCurrent smoking statusConfidence intervalsProportional hazards modelBenign breast tissueBreast cancer prognosisNon-tumor tissuesCrown-like structuresMulti-racial populationEvidence of associationWorse OSWhite patientsClinical outcomesRecord reviewSmoking statusLifestyle factorsMultivariable modelObesity-associated methylation in breast tumors: a possible link to disparate outcomes?
Do W, Conneely K, Gabram-Mendola S, Krishnamurti U, D’Angelo O, Miller-Kleinhenz J, Gogineni K, Torres M, McCullough L. Obesity-associated methylation in breast tumors: a possible link to disparate outcomes? Breast Cancer Research And Treatment 2020, 181: 135-144. PMID: 32236829, DOI: 10.1007/s10549-020-05605-6.Peer-Reviewed Original ResearchConceptsCause mortalityER statusMultivariable Cox proportional hazards modelsCox proportional hazards modelBreast cancer tumor tissuesBreast cancer outcomesBreast cancer incidenceEstrogen receptor statusBody mass indexPrimary risk factorNon-Hispanic blacksCancer tumor tissuesReceptor statusMass indexCancer outcomesCpG sitesRisk factorsCancer incidenceBreast cancerHazards modelBreast tumorsTumor tissueWhite womenObesityRace disparitiesCombined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers
Ogden A, Bhattarai S, Sahoo B, Mongan N, Alsaleem M, Green A, Aleskandarany M, Ellis I, Pattni S, Li X, Moreno C, Krishnamurti U, Janssen E, Jonsdottir K, Rakha E, Rida P, Aneja R. Combined HER3-EGFR score in triple-negative breast cancer provides prognostic and predictive significance superior to individual biomarkers. Scientific Reports 2020, 10: 3009. PMID: 32080212, PMCID: PMC7033213, DOI: 10.1038/s41598-020-59514-1.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic AgentsBiomarkers, TumorCohort StudiesErbB ReceptorsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksHumansMammary Glands, HumanMiddle AgedNeoplasm StagingNF-kappa BPoly (ADP-Ribose) Polymerase-1PrognosisReceptor, ErbB-3Survival AnalysisThioredoxinsTriple Negative Breast NeoplasmsTumor Suppressor Protein p53Diagnosing Anal Squamous Intraepithelial Lesions With and Without p16: An Interobserver Variability Study.
Krishnamurti U, Mohammad M, Monsrud A, Mosunjac M, Oprea G, Hanley K, Tadros T, Flowers L, Mosunjac M. Diagnosing Anal Squamous Intraepithelial Lesions With and Without p16: An Interobserver Variability Study. Journal Of Lower Genital Tract Disease 2020, 24: 69-74. PMID: 31860579, DOI: 10.1097/lgt.0000000000000500.Peer-Reviewed Original Research
2019
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer
Meisel J, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2–Directed Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer 2019, 20: 19-24. PMID: 31806448, DOI: 10.1016/j.clbc.2019.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreastBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantDNA Copy Number VariationsDrug Resistance, NeoplasmFeasibility StudiesFemaleHumansLymphocytes, Tumor-InfiltratingMastectomyMiddle AgedNeoadjuvant TherapyPredictive Value of TestsProgression-Free SurvivalReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTumor BurdenConceptsTumor-infiltrating lymphocytesHER2-positive breast cancerNeoadjuvant therapyHER2/CEP17 ratioBreast cancerClinicopathologic featuresTumor sizeEstrogen receptorKi-67High HER2/CEP17 ratioCEP17 ratioHER2 immunohistochemistry 3Pathologic complete responseProgesterone receptor expressionSmaller tumor sizeBreast cancer responseHigh Ki-67Low estrogen receptorHER2 copy numberRCB-IIPatient ageClinicopathologic factorsComplete responseInitial biopsyExcisional specimensA whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk
Klimov S, Miligy I, Gertych A, Jiang Y, Toss M, Rida P, Ellis I, Green A, Krishnamurti U, Rakha E, Aneja R. A whole slide image-based machine learning approach to predict ductal carcinoma in situ (DCIS) recurrence risk. Breast Cancer Research 2019, 21: 83. PMID: 31358020, PMCID: PMC6664779, DOI: 10.1186/s13058-019-1165-5.Peer-Reviewed Original ResearchConceptsDCIS patientsRecurrence riskDuctal carcinomaScreen-detected breast cancerLong-term outcome dataBreast-conserving surgeryUnmet clinical needNottingham University HospitalsPositive predictive valueAdjuvant radiationIpsilateral recurrenceAdditional therapyMethodsThe cohortHazard ratioLocal recurrenceClinicopathological markersClinicopathological variablesPrimary tumorUniversity HospitalLymphocyte regionBreast cancerOutcome dataBenign ductsPredictive valuePatients
2017
Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients
Li X, Yang J, Krishnamurti U, Huo L, Ward K, O'Regan R, Peng L. Hormone Receptor-Positive Breast Cancer Has a Worse Prognosis in Male Than in Female Patients. Clinical Breast Cancer 2017, 17: 356-366. PMID: 28576631, DOI: 10.1016/j.clbc.2017.03.005.Peer-Reviewed Original ResearchConceptsMale breast carcinomaFemale breast carcinomaHormone receptorsMBC patientsWorse OSOverall survivalBreast carcinomaBreast cancerStage IHormone receptor-positive breast cancerEarly-stage hormone receptorReceptor-positive breast cancerNational Cancer Institute's SurveillanceEnd Results (SEER) databaseWorse overall survivalBreast carcinoma casesSimilar survival ratesMBC subtypesWorse survivalClinicopathologic featuresOverall incidenceResults databaseWorse prognosisHER2 statusFBC patientsDistinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations
Wright N, Xia J, Cantuaria G, Klimov S, Jones M, Neema P, Il’yasova D, Krishnamurti U, Li X, Reid M, Gupta M, Rida P, Osan R, Aneja R. Distinctions in Breast Tumor Recurrence Patterns Post-Therapy among Racially Distinct Populations. PLOS ONE 2017, 12: e0170095. PMID: 28085947, PMCID: PMC5234824, DOI: 10.1371/journal.pone.0170095.Peer-Reviewed Original ResearchConceptsAdjuvant therapyNeoadjuvant chemotherapyRecurrence rateTumor recurrenceClinical studiesBreast cancer recurrence ratesBreast tumor recurrenceCohort of patientsBreast cancer patientsRate of recurrenceCancer recurrence rateAfrican American patientsFirst clinical studyHigh incidence rateEuropean American patientsForm of treatmentLocal recurrenceClinical outcomesPost therapyCancer patientsInvasive diseaseIncidence rateHigher overall rateRecurrence patternsHigh risk
2016
Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Li X, Krishnamurti U, Bhattarai S, Klimov S, Reid M, O’Regan R, Aneja R. Biomarkers Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. American Journal Of Clinical Pathology 2016, 145: 871-878. PMID: 27298399, DOI: 10.1093/ajcp/aqw045.Peer-Reviewed Original ResearchConceptsPathologic complete responseNeoadjuvant chemotherapyEstrogen receptorComplete responseLuminal subtypeProgesterone receptorBreast cancerTriple-negative breast cancer subtypeNottingham grade 3Stromal lymphocytic infiltrationNegative breast cancer subtypeBreast cancer patientsBreast cancer subtypesHigh mitotic countPR negativityHER2 positivityOverall cohortLymphocytic infiltrationTNBC subtypesCancer patientsHER2 statusPathologic parametersKi67 indexNuclear gradeClinical data
2007
Analysis of loss of heterozygosity in atypical and negative bile duct brushing cytology specimens with malignant outcome: are "false-negative" cytologic findings a representation of morphologically subtle molecular alterations?
Krishnamurti U, Sasatomi E, Swalsky P, Finkelstein S, Ohori N. Analysis of loss of heterozygosity in atypical and negative bile duct brushing cytology specimens with malignant outcome: are "false-negative" cytologic findings a representation of morphologically subtle molecular alterations? Archives Of Pathology & Laboratory Medicine 2007, 131: 74-80. PMID: 17227126, DOI: 10.5858/2007-131-74-aolohi.Peer-Reviewed Original ResearchConceptsK-ras mutationsBile duct brushingsLoss of heterozygosityMalignant outcomeFractional allelic lossDuct brushingsCytology casesAllelic lossMolecular alterationsBile duct brushing cytologyPilot studyConventional cytologic evaluationSurgical pathology specimenCorresponding surgical specimensDuct brushing cytologySurgical pathology specimensDetection of malignancySubtle molecular alterationsSurgical outcomesSurgical specimenPathology specimenCytologic findingsSurgical specimensBrushing cytologyCytologic evaluation
2005
Microdissection-based mutational genotyping of serous borderline tumors of the ovary.
Krishnamurti U, Sasatomi E, Swalsky P, Jones M, Finkelstein S. Microdissection-based mutational genotyping of serous borderline tumors of the ovary. International Journal Of Gynecological Pathology 2005, 24: 56-61. PMID: 15626917.Peer-Reviewed Original Research